Ruth Devenyns is the founder of Precirix. Precirix has raised $124M in total funding. Latest round: Series B. Backed by INKEF Capital, Jeito Capital, Forbion.
Ruth Devenyns is the CEO of Precirix, a Brussels-based clinical-stage biotechnology company developing precision radiopharmaceuticals for oncology. Under her leadership, Precirix raised a €37 million Series A in 2018 and a €80 million Series B in December 2021. She previously served as CEO during the company's transition from its original name, Camel-IDS, to Precirix.
Full founder directory · Investor directory · Company funding database · Fundraising library